Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting

TORRANCE, Calif.: TORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced positive transfusion data from a post-hoc analysis of its phase 3 clinical study of Endari®, the company's prescription L-glutamine oral...

Click to view original post